Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture.

This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain for yeast, and who are receiving treatment with antifungal therapy.


Clinical Trial Description

One blood culture and one set of T2clinical specimens will be collected at specified intervals to monitor the clearance of Candida infection from the bloodstream.

Each T2 result will be compared to the companion blood culture result. The comparison will determine if the presence of antifungal therapy inhibits blood culture and leads to an incidence of blood culture false negative test results. The T2 result, which is not impacted by the presence of antifungal therapy, can show that the pathogen is still present for some additional period of time. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02163889
Study type Observational
Source T2 Biosystems
Contact
Status Completed
Phase
Start date September 2014
Completion date April 2017

See also
  Status Clinical Trial Phase
Terminated NCT01982071 - A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Phase 4
Completed NCT02244606 - Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis Phase 2
Recruiting NCT01438216 - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients N/A
Not yet recruiting NCT01249313 - Risk Factor and Outcome of Candidemia N/A
Terminated NCT01213823 - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Phase 4
Completed NCT00940017 - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Phase 4
Completed NCT00105144 - Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Phase 3
Completed NCT03667690 - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Phase 3
Completed NCT03604705 - An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia Phase 2
Completed NCT00607763 - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00608335 - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Recruiting NCT04147975 - Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
Completed NCT01734525 - Negative Beta Glucan in ICU Patients Phase 4
Withdrawn NCT01622595 - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients N/A
Completed NCT03363841 - Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) Phase 3
Completed NCT03799172 - Echinocandins Versus Azoles for Candidemia Treatment
Completed NCT01406093 - Early- and Late-onset Candidemia N/A
Completed NCT00670657 - CRITIC - Treatment of Candidemia and Invasive Candidiasis Phase 4
Completed NCT00113191 - Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants N/A
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3